查詢結果分析
相關文獻
- Intravitreal Bevacizumab for Treating Exudative Retinal Detachment in Coats Disease
- 單側柯氏症合併對側先天性視網膜血管巨大症--病例報告
- Retinal Capillary Hemangiomas: Clinical Manifestations and Visual Prognosis
- 玻璃體內注射癌思停於新生血管性青光眼治療之角色
- A Refractory Germ Cell Tumor Successfully Treated with Bevacizumab in Combination with Paclitaxel
- Chemotherapy Combination with Bevacizumab for the Treatment of Vascular Sarcoma
- The Advantage of Bevacizumab in Treating Colorectal Brain Metastasis
- 治療因使用癌思停(Bevacizumab)治療轉移性直腸癌導致之腸穿孔
- Bevacizumab in Combination with Chemotherapy for Recurrent Ovarian and Peritoneal Cancer: Experience of 27 Patients in One Taiwan Medical Center
- 成功治療因使用癌思停(Bevacizumab)治療轉移性結直腸癌導致之腸穿孔
頁籤選單縮合
題名 | Intravitreal Bevacizumab for Treating Exudative Retinal Detachment in Coats Disease=玻璃體內注射癌思停以治療柯氏症併發的滲出性視網膜剝離 |
---|---|
作者 | 羅育倫; 胡朝乾; | 書刊名 | 輔仁醫學期刊 |
卷期 | 8:4 2010.12[民99.12] |
頁次 | 頁183-189 |
分類號 | 416.746 |
關鍵詞 | 癌思停; 柯氏症; 滲出性視網膜剝離; Coats disease; Exudative retinal detachment; Bevacizumab; OCT; Optical coherence tomography; |
語文 | 英文(English) |
中文摘要 | 本文宗旨:報告使用玻璃體內注射癌思停以治療一位柯氏症併發滲出性視網膜剝離的病例。方法:回顧性病例報告。結果:一位十五歲男孩的左眼罹患第三期早期柯氏症,併發視網膜下水腫與滲出性視網膜剝離,接受了一次玻璃體內注射癌思停治療。治療後中央視網膜厚度由882μm進步到347μm,三個月後滲出性視網膜剝離幾乎完全復位。最佳矯正視力由三十公分辨別手指數進步到3/60。結論:玻璃體內注射癌思停可有效的減少視網膜下積液,因而支持柯氏症的病理機轉可能與血管內皮生長因子相關因素有所關聯。 |
英文摘要 | Background and purpose: To report a case of Coats disease with exudative retinal detachment treated with an intravitreal bevacizumab injection. Methods: Retrospective interventional case report. Results: A 15-year-old boy with early stage 3 Coats disease of the left eye with subretinal exudation and exudative retinal detachment underwent a single injection of intravitreal bevacizumab. A marked reduction in the central retinal thickness (882 to 347 μm) and nearly complete reattachment of retina were noted 3 months after treatment. The best corrected visual acuity improved from counting fingers at 30 cm to 3/60. Conclusions: Intravitreal bevacizumab effectively reduced the subretinal fluid and suggests a vascular endothelial growth factor-mediated component in the pathogenesis of Coats disease in this patient. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。